Corcept Therapeutics Inc (CEPT:NASDAQ)
$6.35 0.22 (3.5889%)
Analysed Corcept Therapeutics Inc (CEPT:NASDAQ) News Sources
Tokenization Platform Securitize To Go Public Via SPAC Deal
21-05-2026
cryptoprowl.com
Securitize and Computershare Partner to Bring Tokenized Shares to U.S. Issuers
29-04-2026
cryptoprowl.com
Securitize, Jump and Jupiter Bring Regulated Tokenized Equity Trading Onchain
05-05-2026
cryptoprowl.com
BlackRock-Linked Securitize Eyes NYSE Debut With $400 Million Haul As SPAC Redemptions Stay Low
27-06-2026
stocktwits.com
Securitize is latest crypto company to go public as BlackRock-backed firm sees stock jump 3% on debut
02-07-2026
yahoo.com
Stripe eyes PayPal with reported $53 billion offer
15-07-2026
yahoo.com
Securitize Revenue Rises 39% Ahead of Planned Cantor SPAC Deal
20-05-2026
cryptoprowl.com
Securitize Lists on NYSE as SECZ: Backed by $400M Raise and BlackRock BUIDL
30-06-2026
cryptonews.com
A New Era for Tokenization: Securitize Lists on the NYSE
03-07-2026
cryptoprowl.com
'Massive Disruptive Potential': Benchmark Initiates Securitize Coverage With Buy Rating
31-03-2026
decrypt.co
What is the current price of Corcept Therapeutics Inc (CEPT:NASDAQ)?
The current price of Corcept Therapeutics Inc (CEPT:NASDAQ) is $6.35.
Corcept Therapeutics Inc (CEPT:NASDAQ) absolute price change since previous trading day?
The absolute price change of Corcept Therapeutics Inc (CEPT:NASDAQ) since the previous trading day is $0.22.
Corcept Therapeutics Inc (CEPT:NASDAQ) percentage price change since previous trading day?
The percentage price change of Corcept Therapeutics Inc (CEPT:NASDAQ) since the previous trading day is 3.5889%.
What is the most recent average sentiment score for Corcept Therapeutics Inc (CEPT:NASDAQ)?
The most recent average sentiment score for Corcept Therapeutics Inc (CEPT:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for Corcept Therapeutics Inc (CEPT:NASDAQ)?
The most recent sentiment for Corcept Therapeutics Inc (CEPT:NASDAQ) is .
SEC-8K** Filing Available For Corcept Therapeutics Inc (CEPT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.